Aclarion, Inc. (Nasdaq: ACON, ACONW) has published a shareholder letter from Chief Executive Officer Brent Ness, updating investors on the company's strategic momentum and key catalysts for 2026. The letter, available on the company's website, highlights progress in expanding adoption of its Nociscan platform for chronic low back pain, growing clinical evidence, and advancing reimbursement initiatives in the United Kingdom and the United States.
The company is pursuing reimbursement coverage from one or more regional insurance providers in the United States, which it views as a critical step toward broader payer adoption. Ness emphasized that disciplined execution against these catalysts could expand Nociscan's reach and strengthen the clinical and reimbursement foundation of the business. The letter also notes an initial readout from the ongoing CLARITY clinical trial expected in the fourth quarter of 2026, following patient enrollment and early interim data disclosure later this year.
Aclarion's balance sheet remains strong, with a cash runway extending into 2028, supporting continued operations and commercial engagement with physicians and imaging centers. The company's Nociscan platform uses magnetic resonance spectroscopy (MRS), proprietary signal processing, biomarkers, and augmented intelligence algorithms to noninvasively help physicians distinguish between painful and nonpainful lumbar discs. When used with other diagnostic tools, Nociscan provides critical insights into the location of low back pain, enabling optimized treatment strategies.
Ness stated, "With increasing physician engagement, growing clinical evidence, and continued progress with payers, we believe Aclarion is well positioned to advance our mission of building a scalable technology platform for chronic low back pain while creating long-term value for patients and shareholders." The company's latest news and updates are available in its newsroom.
Aclarion is a commercial-stage healthcare technology company that leverages biomarkers and proprietary AI algorithms to improve clinical treatments for chronic low back pain. The Nociscan platform is the first evidence-supported, SaaS-based system to noninvasively aid physicians in identifying painful discs in the lumbar spine. By analyzing MRS data from MRI machines, the platform quantifies chemical biomarkers associated with disc pain and uses algorithms to indicate potential pain sources.
The forward-looking statements in the press release include expectations regarding patient enrollment, interim data readouts, the potential benefits of Nociscan, and future regulatory and commercialization activities. These statements are subject to risks and uncertainties detailed in Aclarion's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended December 31, 2025.
